NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., trading under the ticker BRPA on Nasdaq, is the product of a business combination with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners. The SPAC completed its initial public offering in 2017, targeting the healthcare and biopharmaceutical sector. NRX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treatments for critical COVID-19 complications and severe psychiatric conditions, including its lead candidate NRX-101 for bipolar depression. The 10-Q filed on November 16, 2020, with accession number 0001654954-20-012511, reflects the company's financial position during an active period of clinical development and regulatory engagement. Sign up for full data, filings, and deal analytics on SpacDesk.